Who
Andrew Cheng
Director
Company insider
Files Form 4 as: Director, Damora Therapeutics; Director, Vera Therapeutics; President and CEO, Akero Therapeutics; Director, Arbutus Biopharma.
In numbers
- Trades disclosed
- 242
- Buys
- 0
- Sells
- 52
- Bought
- $0
- Sold
- $43.4M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 17 Aug 2019
- Last trade
- 12 Aug 2026
- Last filed
- 13 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 13 Aug 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,350 at $0.00 | filing |
| 12 Aug 2026filed 13 Aug 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,350 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,084 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,084 at $0.00 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —3,421 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —5,032 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,328 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —4,739 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —3,527 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —292,179 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —374,985 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —233,252 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —23,809 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —165,289 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —87,220 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —238,973 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —234,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeutics | SEC FORM 4 Code D | —277,075 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeutics | SEC FORM 4 Code D | —159,762 | filing |
News
No headline names them, or the companies they trade most, lately.